Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
复制标题
结直肠癌中癌症干细胞标志物 ALDH1 表达的预后价值：系统评价和荟萃分析
DOI：
10.1371/journal.pone.0145164
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Shu X
中科院分区：
文献类型：
--
作者：
Chen J;Xia Q;Jiang B;Chang W;Yuan W;Ma Z;Liu Z;Shu X
目的乙醛脱氢酶1（aldehyde dehydrogenase 1，ALDH 1）在结直肠癌（colorectal cancer，CRC）患者预后及临床病理学中的价值仍存在争议。因此，我们进行了这项研究，以澄清ALDH 1高表达在大肠癌和其对生存和临床病理特征的影响之间的关系。方法检索Pubmed、科克伦图书馆、Embase和中国知网（CNKI）截至2015年4月的相关研究文献。仅纳入了描述CRC中ALDH 1抗原与免疫组化的文章。采用RevMan 5.1软件分析5年总生存期（OS）、无病生存期（DFS）及临床病理特征。结果共纳入9篇文献，1203例患者。免疫组织化学染色显示ALDH 1高表达率为46.5%。ALDH 1高表达作为独立预后因素与5年OS和DFS显著相关（OR = 0.42，95%CI：0.26-0.68，P = 0.0004; OR = 0.38，95%CI：0.24-0.59，P < 0.0001）。ALDH 1高表达与肿瘤T分期高度相关（T3 + T4 vs. T1 + T2; OR = 2.16，95%CI：1.09-4.28，P = 0.03），淋巴结（N）分期（N1 + N2 vs. N 0; OR = 1.8; 95%CI：1.17-2.79，P = 0.008）和肿瘤分化（G3 vs. G1 + G2; OR = 1.88; 95%CI：1.07-3.30，P = 0.03）。然而，ALDH 1高表达与患者年龄无显著相关性（>60岁vs. <60岁; OR = 1.11，95%CI：0.63-1.94，P = 0.72）。结论ALDH 1高表达提示结直肠癌患者预后不良。此外，ALDH 1高表达与T分期、N分期和肿瘤分化相关，但与年龄无关。
Objective Many studies have indicated the prognostic and clinicopathological value of aldehyde dehydrogenase 1 (ALDH1) in colorectal cancer (CRC) patients still remains controversial. Thus we performed this study to clarify the relationship between high ALDH1 expression in CRC and its impact on survival and clinicopathological features. Methods Publications for relevant studies in Pubmed, the Cochrane Library, Embase, and China National Knowledge Infrastructure (CNKI) through April 2015 were identified. Only articles describing ALDH1 antigen with immunohistochemistry in CRC were included. The software RevMan 5.1 was used to analyze the outcomes, including 5-year overall survival (OS), disease-free survival (DFS) and clinicopathological features. Results 9 studies with 1203 patients satisfying the criteria were included. The overall rate of high ALDH1 expression was 46.5% by immunohistochemical staining. High ALDH1 expression as an independent prognostic factor was significantly associated with the 5-year OS and DFS (OR = 0.42, 95%CI: 0.26–0.68, P = 0.0004; OR = 0.38, 95%CI: 0.24–0.59, P < 0.0001, respectively). High ALDH1 expression was highly correlated with the tumor (T) stage (T3 + T4 vs. T1 + T2; OR = 2.16, 95%CI: 1.09–4.28, P = 0.03), lymph node (N) stage (N1 + N2 vs. N0; OR = 1.8; 95%CI: 1.17–2.79, P = 0.008), and tumor differentiation (G3 vs. G1 + G2; OR = 1.88; 95%CI: 1.07–3.30, P = 0.03). However, high ALDH1 expression was not significantly correlated with the patient age (>60 years old vs. <60 years old; OR = 1.11, 95%CI: 0.63–1.94, P = 0.72). Conclusions High ALDH1 expression indicates a poor prognosis in CRC patients. Moreover, high ALDH1 expression correlates with the T stage, N stage, and tumor differentiation, but not with age.